Biomimetic solutions for hemorrhage control

Calder is a nano-scale, molecular engineering company that is applying its platform technology to engineer and develop novel vaccines that allow billions of people to stay healthy. We’re developing safe, effective, durable, and tolerable vaccines that protect against RSV, all strains of seasonal and pandemic influenza, and other harmful, viral infections.

Protonintel provides continuous, real-time, and accurate biomarker monitoring to better manage chronic disease and save lives. The ProtonPetal will be the only solution to provide accurate and real-time potassium (K+) measurements in the interstitial fluid of the skin continuously for heart and kidney care. Data from the ProtonPetal can be monitored by clinicians and end […]

Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications.

A2A Pharmaceuticals has designed new drug candidates for cancers like Leukemia and other life threatening diseases. A2A’s technology platform optimizes the efficacy of such options while minimizing toxicity much faster and more precisely than competitors. We build and evaluate small molecule libraries that consist of thousands to millions of members until we obtain candidates with […]

Able Sciences, Inc. (Able) is deploying a leading-edge RNA technology platform to develop highly differentiated off-the-shelf, cost-effective cell therapies leading with allogeneic NK cells to cure Solid Cancers and Autoimmune Disorders.

ANA Therapeutics developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. ANA Therapeutics was acquired by NeuroBo Pharmaceuticals in 2020.

Glycans are complex sugars that coat proteins and dictate how cells and tissues behave. Glycan-driven mechanisms sit at the core of immune and fibrotic diseases and contribute to up to 25% of global disease burden, yet 96% of FDA-approved drugs target proteins. Anomer Bio’s proprietary platform integrates multi-omics data, a Nobel Prize-winning research tool and […]

Our technology combines 211-Astatine, the most druggable alpha-emitting radioisotope, with multivalent single-domain antibodies to deliver potent alpha radiation that breaks DNA strands and kills the tumor cells while leaving normal cells unaffected.

Life is programmed by three classes of biopolymers: polynucleotides (DNA/RNA), polypeptides (proteins), and polysaccharides (glycans). We’ve learned to “write” genes and proteins like software, but glycosylation is still a finicky, expensive manufacturing problem. That’s a big deal: the wrong glycan can slash an antibody’s efficacy, trigger allergic reactions, or turn a multi-million-dollar batch into scrap. […]